Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glatiramer acetate therapy for multiple sclerosis: a review.
Perumal J, Filippi M, Ford C, Johnson K, Lisak R, Metz L, Tselis A, Tullman M, Khan O. Perumal J, et al. Among authors: ford c. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):1019-29. doi: 10.1517/17425255.2.6.1019. Expert Opin Drug Metab Toxicol. 2006. PMID: 17125414 Review.
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Ford CC, Cohen JA, Goodman AD, Lindsey JW, Lisak RP, Luzzio C, Pruitt A, Rose J, Rus H, Wolinsky JS, Kadosh SE, Bernstein-Hanlon E, Stark Y, Alexander JK. Ford CC, et al. Mult Scler. 2022 Oct;28(11):1729-1743. doi: 10.1177/13524585221094239. Epub 2022 Jun 29. Mult Scler. 2022. PMID: 35768939 Free PMC article. Clinical Trial.
The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer Acetate Extension Study.
Khan O, Seraji-Bozorgzad N, Bao F, Razmjou S, Caon C, Santiago C, Latif Z, Aronov R, Zak I, Ashtamker N, Kolodny S, Ford C, Sidi Y. Khan O, et al. Among authors: ford c. J Neuroimaging. 2017 Jan;27(1):97-106. doi: 10.1111/jon.12358. Epub 2016 May 23. J Neuroimaging. 2017. PMID: 27214389 Free PMC article. Clinical Trial.
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.
Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J. Ford C, et al. Mult Scler. 2010 Mar;16(3):342-50. doi: 10.1177/1352458509358088. Epub 2010 Jan 27. Mult Scler. 2010. PMID: 20106943 Free PMC article. Clinical Trial.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: ford cc. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.
1,846 results